• Explore /
  • Poster
  • / A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Neeraj Agarwal

Neeraj Agarwal

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Neeraj Agarwal , Arun Azad , Joan Carles , Simon Chowdhury , Bradley Alexander McGregor , Axel Stuart Merseburger , Stephane Oudard , Fred Saad , Andrey Soares , Ashok Panneerselvam , Fong Wang , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Advanced Prostate Cancer

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04446117

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS190)

DOI

10.1200/JCO.2021.39.6_suppl.TPS190

Abstract #

TPS190

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Melissa Andrea Reimers

First Author: Neeraj Agarwal

First Author: Karim Fizazi

First Author: Daniel Peter Petrylak